Luciferase reporter test system for early identification of liver-damaging agents
CompanyINDIGO Biosciences, Inc., State College, USA
Drug-induced hepatotoxicities are one of the main reasons why new drugs fail in the clinical development phase. To optimize the early detection of drug-induced liver damage, INDIGO Biosciences has developed a standardized all-inclusive assay system that enables precise and easily reproducible analyses. The test kits contain two samples of cryopreserved reporter cells, two cell culture-ready assay plates, luciferase detection reagent, all necessary cell culture media (CCM) for cell thawing, seeding and preparation of treatment media, and a reference compound that provides a positive control for liver toxicity. INDIGO uses human liver cells that were developed by upcyte® technologies GmbH. The highly differentiated hepatocytes show limited proliferation while maintaining their native properties, as well as high cell viability under culture conditions. The prediction is evaluated by quantitative measurements of the luminescent response of the bioluminescent enzyme, luciferase, integrated into the reporter cells. The test system thereby enables effective screening for the induction and activity of hepatic drug metabolizing enzymes (DME), which are associated with certain liver diseases (such as non-alcoholic fatty liver disease, steatosis, or cholestasis). In summary, the luciferase reporter assay can help improve drug development and reduce the risk of clinical study participants and patients by detecting the enzymatic initiation of liver-damaging processes early and safely.
In vitro screening for drug-induced hepatotoxicity assay kit
www.indigobiosciences.com
Added on: 02-13-2024
[1] https://indigobiosciences.com/product/in-vitro-screening-for-drug-induced-hepatotoxicity-assay-kit/[2] https://www.upcyte.com/read/hepatocytes-1315.html
